FindTrial
Sign In

Conbercept combined with Iodine-125 Plaque Therapy treating for uveal melanoma- an exploratory clinical study

Conbercept combined with Iodine-125 Plaque Therapy treating for uveal melanoma- an exploratory clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17013862
Enrollment
Unknown
Registered
2017-12-13
Start date
2016-04-01
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveal Melanoma

Interventions

intervention group:intraocular injection of Conbercept(KH902) with a dose at 0.5mg at the time points of plaque removal and the month 1, 2, 5, 8, 11 after plaque removal

Sponsors

Beijing Tongren Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged>18 years; 2. Sufferred from the primary uveal melanoma ,and height is among 4-8mm, diameter<16mm; 3. No affect the macular or optical disc, no extraocular diffuse and metastasis.

Exclusion criteria

Exclusion criteria: 1. Radiation treatment or surgical history of the affected eye; 2. Pregnancy or suckling period; 3. Unable to participate one-year follow-up.

Design outcomes

Primary

MeasureTime frame
survival;metastasis;tumor volume;Best corrected visual acuity;rate of exuadative retinal detachment;—

Countries

China

Contacts

Public ContactWen-bin Wei

Beijing Tongren Hospital, Capital Medical University

tr_weiwenbin@163.com+86 13701255115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026